Alembic Pharmaceuticals Receives USFDA Approval for Generic Venclexta With 180-Day Exclusivity Eligibility
Alembic Pharmaceuticals Ltd 路 Press Release 路 30 Oct 2026, 11:59 pm
Alembic Pharmaceuticals Receives USFDA Approval for Generic Venclexta With 180-Day Exclusivity Eligibility Alembic Pharmaceuticals received USFDA final approval on 30th Oct'26 for its ANDA for Venetoclax Tablets (10 mg, 50 mg, and 100 mg), generic to AbbVie's Venclexta. As a first-to-file Paragraph IV applicant, Alembic may be eligible for 180 days of generic exclusivity. The product addresses CLL, SLL, and AML indications, targeting an estimated US market size of US $1,584 million for the twelve months ending Jun'26. Alembic now holds a cumulative total of 248 USFDA ANDA approvals, comprising 228 final and 20 tentative approvals.
Original exchange filing (PDF)
More announcements from Alembic Pharmaceuticals Ltd
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Binimetinib Tablets, 15 mg and 45 mg. 路 15 Nov 2026
- Please find attached herewith the Transcript of Post Results Conference Call held on 4th November, 2026. 路 10 Nov 2026
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). 路 05 Nov 2026
- Please find attached Audio Recording of Investor Call. 路 05 Nov 2026
- Please find attached intimation under Regulation 30(5) of SEBI (LODR) Regulations, 2015. 路 04 Nov 2026
- Please find attached Press Release 路 04 Nov 2026
- Please find attached Investor Presentation for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
- Please find attached Press Release for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
